


Doctor On Demand Merges With Grand Rounds
Telehealth provider Doctor On Demand announced plans last week to merge with Grand Rounds to form a new company centered around virtual care. Doctor On Demand provides a full suite of personalized Total Virtual Care services including primary care, integrated behavioral health, everyday and urgent care, chronic condition management, and prevention. The company delivers services through employers, health plans, Medicare Part B, and directly to consumers. Grand Rounds provides care coordination and expert medical opinions, and it helps clients understand and navigate health care insurance benefits. No terms for the merger were... Read More »
The Stepping Stones Group Expands Into Philly
The behavioral health services provider, The Stepping Stones Group, has pushed into the Philadelphia market with the purchase of EBS Healthcare, a not-for-profit based in West Chester, Pennsylvania. EBS Healthcare is a therapeutic and behavioral company that employs speech-language pathologists, occupational therapists and physical therapists. The company also has a division called the EBS Children’s Institute, a leading research, training and teaching organization working to advance the field of special education and pediatric therapy. EBS treats roughly 2.1 million patients each year. With the addition of EBS Healthcare, the combined company will have a client base... Read More »
Health Care M&A Deals, March 19, 2021
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week by disclosed price is Roche Holding AG’s acquisition of GenMark Diagnostics for $1.8 billion. GenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics and reduce the total cost-of-care. GenMark’s eSensor XT-8 and ePlex systems are designed to support a... Read More »
Roche Holding Acquires GenMark Diagnostics
Last week, the pharmaceutical giant Roche Holding AG (SIX: RO) announced a new acquisition for GenMark Diagnostics (NASDAQ: GNMK), a Carlsbad, California lab services company. GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics and reduce the total cost-of-care. GenMark’s eSensor XT-8 and ePlex systems are designed to support a broad range of molecular diagnostic sample-to-answer tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. The deal is valued at $1.8 billion cash, or $24.05 per share, a premium of... Read More »
DocGo Goes Public Via SPAC
Another week, another SPAC deal. Ambulnz, Inc., dba DocGo, has announced it is merging with Motion Acquisition Corp. (NASDAQ: MOTN), a special purpose acquisition company to create a publicly traded entity. DocGo, based in New York City, provides last-mile telehealth and integrated medical mobility services. Its medical mobility services offer on-demand service response and real-time vehicle location, as well as accurate estimated arrival times. The company serves 23 states in the U.S. and has operations in the U.K. By going public, DocGo hopes to continue growing its geographic footprint. The combined company has a pro forma equity value of approximately $1.1 billion and will have... Read More »
Takeda Adds Maverick Therapeutics
The pharmaceutical giant Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) is back with a new acquisition. The company has announced the acquisition of Maverick Therapeutics, Inc for a pre-negotiated upfront payment as well as potential development and regulatory milestones totaling up to $525 million. This acquisition follows a multi-year collaboration between Takeda and Maverick, signed in 2017. Maverick Therapeutics is a privately held biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies. Its lead candidates are MVC-280 (now TAK-280) and MVC-101 (now TAK-186). TAK-186 is currently in a Phase 1/2 study for the treatment of EFGR-expressing solid... Read More »
Quest Diagnostics Acquires Lab Division from Mercy
In an effort to expand its network, Quest Diagnostics (NYSE: DGX) has announced a deal with not-for-profit Mercy, a multi-state healthcare system. Quest is acquiring the health system’s outreach laboratory services business, which currently operates from 29 hospital laboratories and two independent clinic laboratories in Arkansas, Kansas, Missouri and Oklahoma. No terms were disclosed in the all-cash transaction, but under the agreement, testing associated with outreach lab services will transition to the Quest Diagnostics full-service laboratory in Lenexa, Kansas, and a network of rapid response laboratories across the region. Mercy will continue to wholly own and operate its hospital... Read More »
Health Care M&A Deals, March 12, 2021
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week by disclosed price is DocGo’s reverse merger with Motion Acquisition Corp. (NASDAQ: MOTN), a special purpose acquisition company to create a publicly traded entity. DocGo, based in New York City, provides last-mile telehealth and integrated medical mobility services. Its medical mobility services offer on-demand service response and real-time... Read More »